Evidence map›Paper›PMID 33401758›Full record

ArticleCancers2021

Mutation of the Cell Cycle Regulator p27kip1 Drives Pseudohypoxic Pheochromocytoma Development.

Hermine Mohr, Simone Ballke, Nicole Bechmann, Sebastian Gulde, Jaber Malekzadeh-Najafabadi, Mirko Peitzsch, Vasilis Ntziachristos, Katja Steiger, Tobias Wiedemann, Natalia S Pellegata

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. COX4I2 is a novel biomarker of blood supply in adrenal tumors.Translational andrology and urology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Hermine MohrInstitute for Diabetes and Cancer, Helmholtz Centre Munich, Ingolstaedter Landstr.1, 85764 Neuherberg, Germany.
Simone BallkeInstitute of Pathology, School of Medicine, Technical University Munich, Trogerstr. 18, 81675 Munich, Germany.
Nicole BechmannDepartment of Medicine III, University Hospital Carl Gustav Carus, Technical University Dresden, Fetscherstrasse 74, 01307 Dresden, Germany.ORCID 0000-0002-6932-333X
Sebastian GuldeInstitute for Diabetes and Cancer, Helmholtz Centre Munich, Ingolstaedter Landstr.1, 85764 Neuherberg, Germany.
Jaber Malekzadeh-NajafabadiChair of Biological Imaging, Technical University of Munich, Ismaninger Straße 22, 81675 Munich, Germany.
Mirko PeitzschInstitute of Clinical Chemistry and Laboratory, University Hospital Carl Gustav Carus, Technical University Dresden, Fetscherstrasse 74, 01307 Dresden, Germany.
Vasilis NtziachristosChair of Biological Imaging, Technical University of Munich, Ismaninger Straße 22, 81675 Munich, Germany.
Katja SteigerInstitute of Pathology, School of Medicine, Technical University Munich, Trogerstr. 18, 81675 Munich, Germany.ORCID 0000-0002-7269-5433
Tobias WiedemannInstitute for Diabetes and Cancer, Helmholtz Centre Munich, Ingolstaedter Landstr.1, 85764 Neuherberg, Germany.
Natalia S PellegataInstitute for Diabetes and Cancer, Helmholtz Centre Munich, Ingolstaedter Landstr.1, 85764 Neuherberg, Germany.
Heidelberg University · DETechnical University of Munich · DEUniversity Hospital Carl Gustav Carus · DEHelmholtz Zentrum München · DE

Funding

Deutsche Forschungsgemeinschaft CRC 824 "Imaging for Selection, Monitoring and Individualization of Cancer Therapies", Project B8, A1/Z3 and Z2Deutsche Forschungsgemeinschaft CRC/Transregio 205/1, Project B11, B12 and S01 "The Adrenal: Central Relay in Health and Disease"
6 · The paper itself

Abstract

backgroundPseudohypoxic tumors activate pro-oncogenic pathways typically associated with severe hypoxia even when sufficient oxygen is present, leading to highly aggressive tumors. Prime examples are pseudohypoxic pheochromocytomas and paragangliomas (p-PPGLs), neuroendendocrine tumors currently lacking effective therapy. Previous attempts to generate mouse models for p-PPGLs all failed. Here, we describe that the rat MENX line, carrying a

methodsWe compared rat p-PCCs with their cognate human tumors at different levels: histology, immunohistochemistry, catecholamine profiling, electron microscopy, transcriptome and metabolome. The vessel architecture and angiogenic potential of pheochromocytomas (PCCs) was analyzed by light-sheet fluorescence microscopy ex vivo and multi-spectral optoacoustic tomography (MSOT) in vivo.

resultsThe analysis of tissues at various stages, from hyperplasia to advanced grades, allowed us to correlate tumor characteristics with progression. Pathological changes affecting the mitochrondrial ultrastructure where present already in hyperplasias. Rat PCCs secreted high levels of norepinephrine and dopamine. Transcriptomic and metabolomic analysis revealed changes in oxidative phosphorylation that aggravated over time, leading to an accumulation of the oncometabolite 2-hydroxyglutarate, and to hypermethylation, evident by the loss of the epigenetic mark 5-hmC. While rat PCC xenografts showed high oxygenation, induced by massive neoangiogenesis, rat primary PCC transcriptomes possessed a pseudohypoxic signature of high

conclusionEndogenous rat PCCs recapitulate key phenotypic features of human p-PPGLs. Thus, MENX rats emerge as the best available animal model of these aggressive tumors. Our study provides evidence of a link between cell cycle dysregulation and pseudohypoxia.

Indexed as

2-hydroxyglutarate5-hmCangiogenesisanimal modelcell cycleendogenous pheochromocytomahypermethylationMENXmitochondrial dysfunctiononcometabolitesPPGLspseudohypoxia

Identifiers

PMID33401758
PMCPMC7794757
OpenAlexW3119918980

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.